Lionel Velez Montijo, MD
Internal Medicine · Bayamon, PRNPI 1194719542
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,290 of the $5,790 with a category attached, or 74.1%. 16 manufacturers reported payments, led by Merck at 30.4% of the total. Reporting peaked in 2019 at $2,612 and has fallen 88.9% since, to $291 in 2025. Among internal medicine clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 188 payments — averaging $30.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2K
- Boehringer Ingelheim$1K
- AstraZeneca$940
- Eli Lilly Export S.A. Puerto Rico Branch$388
- Johnson & Johnson$306
- Sanofi-aventis U.S. LLC$216
- plus $1K from 10 others
What the payments were for
- Consulting fees$1,50026%
- Food & beverage$4,29074%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 14 | $1,757 |
| Boehringer Ingelheim | 40 | $1,021 |
| AstraZeneca | 48 | $940 |
| Eli Lilly Export S.A. Puerto Rico Branch | 19 | $388 |
| Johnson & Johnson | 14 | $306 |
| Sanofi-aventis U.S. LLC | 10 | $216 |
| Novo Nordisk | 10 | $194 |
| E.r. Squibb & Sons, L.L.C. | 9 | $184 |
| GSK | 5 | $173 |
| Lilly USA, LLC | 3 | $169 |
| PBG Puerto Rico LLC | 7 | $161 |
| Novartis | 1 | $100 |
| Amgen | 4 | $92 |
| Dexcom, Inc. | 2 | $40 |
| AbbVie | 1 | $25 |
| Pfizer | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,790 in reported general payments places this provider in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 426 | $340,647 |
| FarxigaDapagliflozin Propanediol | 301 | $194,514 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 269 | $178,106 |
| GlyxambiEmpagliflozin/Linagliptin | 237 | $168,039 |
| JanuviaSitagliptin Phosphate | 197 | $146,937 |
| ProliaDenosumab | 57 | $100,630 |
| SynthroidLevothyroxine Sodium | 1,484 | $96,766 |
| JanumetSitagliptin Phos/Metformin Hcl | 149 | $96,381 |
| XareltoRivaroxaban | 138 | $92,943 |
| EliquisApixaban | 122 | $91,457 |
| TrulicityDulaglutide | 42 | $49,035 |
| JulucaDolutegravir/Rilpivirine | 13 | $45,240 |
| Spiriva RespimatTiotropium Bromide | 75 | $42,720 |
| LinzessLinaclotide | 66 | $38,026 |
| OzempicSemaglutide | 33 | $32,547 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi, Spiriva Respimat, Jentadueto, Trijardy Xr | $1,021 | $607,477822 claims |
| MerckJanumet Xr, Januvia, Janumet | $1,757 | $421,424615 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $940 | $205,490318 claims |
| AbbVieSynthroid, Linzess, Creon | $25 | $149,5551,566 claims |
| AmgenProlia | $92 | $100,63057 claims |
| Johnson & JohnsonXarelto | $306 | $92,943138 claims |
| PfizerEliquis | $24 | $91,457122 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $169 | $85,173134 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $173 | $48,33798 claims |
| Novo NordiskOzempic | $194 | $32,54733 claims |
| Sanofi-aventis U.S. LLCLantus | $216 | $23,721136 claims |
| NovartisEntresto | $100 | $10,44913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.
Other internal medicine in Bayamon
- Sixto MedinaBayamon$15K
- Graciela Latalladi OrtegaBayamon$11K
- Pedro Roman EyxarchBayamon$9K
- Neisa Torres ReyesBayamon$8K
- Luis FortiBayamon$8K
- Carlos AcostaBayamon$7K
- Jose Aviles MunozBayamon$6K
- Steven CruzBayamon$6K
- Wanda Beltran VirellaBayamon$5K
- Nelson VallejoLas Piedras$621K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.